CompletedPhase 2NCT01438996

Extension Study of H01_04TP to Evaluate the Booster Response Induced by Vi-CRM197 in Adults

Studying Typhoid

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Novartis
Principal Investigator: Pierre Van Damme, MD
Universiteit Antwerpen
Intervention: NVGH Vi-CRM197(biological)
Enrollment: 51 target
Eligibility: 18-42 years · All sexes
Timeline: 2011 – 2011

Study locations (1)

Centre for the Evaluation of Vaccination (CEV), Antwerp, Wilrijk, Belgium

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01438996 on ClinicalTrials.gov

Other trials for Typhoid

Additional recruiting or active studies for the same condition.

ACTIVE NOT RECRUITINGEARLY PHASE1NCT04083950
Induction of Gut Permeability by an Oral Vaccine
USDA, Western Human Nutrition Research Center
ACTIVE NOT RECRUITINGPHASE3NCT03299426
Clinical Efficacy of Typhoid Conjugate Vaccine (Vi-TCV) Among Children Age 9 Months Through 12 Years in Blantyre, Malawi
University of Maryland, Baltimore
ACTIVE NOT RECRUITINGPHASE4NCT03970304
CVD 37000: Immunity and Microbiome Studies at Intestinal and Systemic Sites in Ty21a Vaccinated Adults
University of Maryland, Baltimore

See all trials for Typhoid →

← Back to all trials